Cargando…
Evolution of Direct Costs in the First Years of Rheumatoid Arthritis: Impact of Early versus Late Biologic Initiation - An Economic Analysis Based on the ESPOIR Cohort
OBJECTIVES: To estimate annual direct costs of early RA by resource component in an inception cohort, with reference to four distinct treatment strategies: no disease modifying antirheumatic drugs (DMARDs), synthetic DMARDs only, biologic DMARDs in the first year (‘first-year biologic’, FYB), and bi...
Autores principales: | Chevreul, Karine, Haour, Georges, Lucier, Sandy, Harvard, Stephanie, Laroche, Marie-Laure, Mariette, Xavier, Saraux, Alain, Durand-Zaleski, Isabelle, Guillemin, Francis, Fautrel, Bruno |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4014570/ https://www.ncbi.nlm.nih.gov/pubmed/24811196 http://dx.doi.org/10.1371/journal.pone.0097077 |
Ejemplares similares
-
Matrix to predict rapid radiographic progression of early rheumatoid arthritis patients from the community treated with methotrexate or leflunomide: results from the ESPOIR cohort
por: Fautrel, Bruno, et al.
Publicado: (2012) -
Performance of matrices developed to identify patients with early rheumatoid arthritis with rapid radiographic progression despite methotrexate therapy: an external validation study based on the ESPOIR cohort data
por: Granger, Benjamin, et al.
Publicado: (2016) -
Machine learning predicts response to TNF inhibitors in rheumatoid arthritis: results on the ESPOIR and ABIRISK cohorts
por: Bouget, Vincent, et al.
Publicado: (2022) -
Outcome of patients with early arthritis without rheumatoid factor and ACPA and predictors of rheumatoid arthritis in the ESPOIR cohort
por: Mouterde, Gaël, et al.
Publicado: (2019) -
Cost Effectiveness of Free Access to Smoking Cessation Treatment in France Considering the Economic Burden of Smoking-Related Diseases
por: Cadier, Benjamin, et al.
Publicado: (2016)